资金流向方面，8月21日主力资金净流出1814.92万元，但近五日主力资金整体净流入1.39亿元。 风险提示：市场有风险，投资需谨慎。 截至2025年8月21日收盘，博济医药股价报11.98元，较前一交易日下跌3.07%，成交额达5.67亿元，换 手率为16.61%。 博济医药属于医疗服务行业，主营业务涵盖医药研发外包服务，2024年财报显示，公司99.39%的营收 来自服务业。 消息面上，公司控股股东王廷春及一致行动人计划在未来3个月内减持不超过1148.65万股，占总股本的 3%，减持原因为个人资金需求。 ...

Group 1 - The controlling shareholder, Hong Kong Junyao, reduced its stake in the company by 17.505 million shares, accounting for 1.5% of the total share capital [1] - The reduction took place between June 27, 2025, and July 4, 2025, through block trading [1] - The share price during the reduction ranged from 48.55 yuan to 51.19 yuan per share [1] Group 2 - After the completion of the reduction, Hong Kong Junyao and its concerted party, Zhongshan Hongting, hold a combined shareholding of 85.98%, down from 87.48% [1] - The change in shareholding percentage reached 1% [1]

Group 1 - The controlling shareholder Chengdu Local Construction Machinery Engineering Co., Ltd. and its concerted parties have reduced their shareholding in Huason Pharmaceutical Co., Ltd. from 70.00% to 68.76% through various trading methods [1][2] - A total of 5,193,650 shares were reduced, representing a decrease of 1.24% of the company's total share capital [1][2] - The shareholding structure post-reduction shows that Chengdu Local Construction and its concerted parties now hold 287,123,875 shares [1][2] Group 2 - The reduction of shares was executed in compliance with previously disclosed plans, and the total number of shares reduced is within the limits set by the reduction plan [2][3] - The reduction occurred between January 24, 2025, and June 9, 2025, with specific details on the number of shares sold through block trades and centralized bidding [1][2] - The announcement confirms that the information provided is accurate and complete, with no misleading statements or significant omissions [1]

Core Viewpoint - The controlling shareholder and actual controller of Yiming Pharmaceutical, Gao Fan, is planning to change the company's control, leading to a temporary suspension of the company's stock trading due to significant uncertainty surrounding the matter [1][3]. Group 1: Shareholder Information - Gao Fan, the founder of Yiming Pharmaceutical, holds 48.80 million shares, accounting for 25.59% of the total share capital, making him the largest shareholder [3]. - In September 2021, Gao Fan stepped down from his positions as chairman and general manager of the company but continued to hold a position in a subsidiary [3]. - Following his resignation, Gao Fan initiated a share reduction plan in June 2022, intending to reduce his holdings by up to 9.56 million shares (5% of total shares), but only reduced 635,800 shares (0.33%) by the end of the plan [4]. Group 2: Financial Performance - Yiming Pharmaceutical's revenue from 2020 to 2024 was as follows: 602.62 million, 725.46 million, 856.73 million, 667.04 million, and 651.88 million yuan, respectively, with net profits of 41.09 million, 43.47 million, 46.12 million, 15.73 million, and 47.46 million yuan [7]. - In 2023, the company experienced a 22.14% decline in revenue and a significant 65.9% drop in net profit [7]. - The company attributed the poor performance to changes in market conditions, industry environment, and underperformance of third-party cooperative products [8]. Group 3: Strategic Moves - Yiming Pharmaceutical had previously announced a private placement plan in April 2021, intending to raise between 200 million and 350 million yuan, but the plan was terminated four months later due to market conditions and business development considerations [6]. - The company acquired a 51% stake in Inner Mongolia Bostai Enterprise Management Service Co., Ltd. for 30.6 million yuan in August 2021, but the acquisition faced criticism due to the high premium paid [8].